A Member of the University of Maryland Medical System | In Partnership with the University of Maryland School of Medicine

Get answers to your menopause and sexual dysfunction questions.
Dr. Omicioli’s Bio | Q&A Archive
PMS
Premenstrual syndrome (PMS) is reported in women in many cultures worldwide. About 80% of women in their reproductive years have some emotional and physical symptoms before their periods that impair daily activities. Between 3 - 8% of women report very severe symptoms, notably premenstrual dysphoric disorder (PMDD). A number of factors may put a woman at higher risk for PMS.
The risk for severe PMS is higher in younger women, and onset usually begins around the mid-twenties. Some evidence suggests that PMS symptoms diminish after age 35. Naturally, PMS and any manifestation of it end at menopause.
Women with a history of or susceptibility to depression may be at increased risk for PMS and premenstrual dysphoric disorder (PMDD). Cultural factors may also affect the perception and severity of PMS symptoms.
Studies have found some factors associated with a higher risk for PMS or more severe symptoms, (although the evidence behind these claims is not very strong):
Braverman PK. Premenstrual syndrome and premenstrual dysphoric disorder. J Pediatr Adolesc Gynecol. 2007 Feb;20(1):3-12.
Brown J, O' Brien PM, Marjoribanks J, Wyatt K. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD001396.
Jarvis CI, Lynch AM, Morin AK. Management strategies for premenstrual syndrome/premenstrual dysphoric disorder. Ann Pharmacother. 2008 Jul;42(7):967-78. Epub 2008 Jun 17
Kwan I and Onwude JL. Premenstrual syndrome. BMJ Clinical Evidence. Web publication date: 01 May 2007.
Lentz GM. Primary and secondary dysmenorrheal, premenstrual syndrome, and premenstrual dysphoric disorder. Etiology, diagnosis, management. In: Katz VL, Lobo RA, Lentz G, Gershenson D, eds. Comprehensive Gynecology. 5th ed. St. Louis, MO: Mosby; 2007:chap 36.
Lopez LM, Kaptein AA, Helmerhorst FM. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD006586.
Yonkers KA, O'Brien PM, Eriksson E. Premenstrual syndrome. Lancet. 2008 Apr 5;371(9619):1200-10.
A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is an independent audit to verify that A.D.A.M. follows rigorous standards of quality and accountability. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial policy, editorial process and privacy policy. A.D.A.M. is also a founding member of Hi-Ethics and subscribes to the principles of the Health on the Net Foundation (www.hon.ch).
© 2011 University of Maryland Medical Center (UMMC). All rights reserved.
UMMC is a member of the University of Maryland Medical System,
22 S. Greene Street, Baltimore, MD 21201. TDD: 1-800-735-2258 or 1.800.492.5538